• Tarundeep Kakkar, Cynthia Sung, Leonid Gibiansky, Thuy Vu, Adimoolam Narayanan, Shao-Lee Lin, Michael Vincent, Christopher Banfield, Alex Colbert, Sarah Hoofring, Marta Starcevic, and Peiming Ma.
• Department of Pharmacokinetics and Metabolism, Amgen Inc., Thousand Oaks, California, 91320, USA. tkakkar@amgen.com
• Pharm. Res. 2011 Oct 1; 28 (10): 2530-42.

PurposeFor AMG 317, a fully human monoclonal antibody to interleukin receptor IL-4Rα, we developed a population pharmacokinetic (PK) model by fitting data from four early phase clinical trials of intravenous and subcutaneous (SC) routes simultaneously, investigated important PK covariates, and explored the relationship between exposure and IgE response.MethodsData for 294 subjects and 2183 AMG 317 plasma concentrations from three Phase 1 and 1 Phase 2 studies were analyzed by nonlinear mixed effects modeling using first-order conditional estimation with interaction. The relationship of IgE response with post hoc estimates of exposure generated from the final PK model was explored based on data from asthmatic patients.ResultsThe best structural model was a two-compartment quasi-steady-state target-mediated drug disposition model with linear and non-linear clearances. For a typical 80-kg, 40-year subject, linear clearance was 35.0 mL/hr, central and peripheral volumes of distribution were 1.78 and 5.03 L, respectively, and SC bioavailability was 24.3%. Body weight was an important covariate on linear clearance and central volume; age influenced absorption rate. A significant treatment effect was observable between the cumulative AUC and IgE response measured.ConclusionThe population PK model adequately described AMG 317 PK from IV and SC routes over a 60-fold range of doses with two dosing strengths across multiple studies covering healthy volunteers and patients with mild to severe asthma. IgE response across a range of doses and over the sampling time points was found to be related to cumulative AMG 317 exposure.

28 keywords...

hide…